- Email: [email protected]
OI0268 Nonaromatic naphthalan for the treatment of oral mucosal diseases
ORAL MEDICINE e382 Abstracts at the correlation between the diagnosis in the referral letter and the actual clinical diagnosis, to assess the time frame between the referral date and the first visit, and to develop an integrated clinical care pathway for pediatric patients with oral mucosal or salivary gland disease. Methods: This was a retrospective case-note evaluation (January 2011 to December 2011). Patients were seen on new patient clinics either in pediatrics or oral medicine. A data extraction form was developed and information recorded and analyzed. The standards were that all clinical notes should have a referral letter, and that all patients be seen within 18 weeks. All patients’ notes should have a letter back to the referring practitioner, and there should be an 80% correlation between the actual diagnosis and that in the referral letter. Results: Results were looked at for 110 patients. Oral ulceration was the most common condition diagnosed. Almost all patients referred (98%) had a referral letter. It was found that 88% of children were seen within 18 weeks. All patients’ notes had a letter back to the referring practitioner, and there was a 75% correlation between actual diagnosis and diagnosis made in the referral letter. This audit highlighted the range of diagnoses made by the specialists compared with the diagnoses made in the referrals, which found 25% of the diagnoses not identified correctly. Conclusions: Overall, the standards were partially met. There is a need to streamline these patients to meet the target of 18 weeks with the introduction of a joint oral medicine / pediatric clinic. Data can be used for research, and a template will be developed for referral of patients. There will be a repeat audit after 12 months.
OI0268 NONAROMATIC NAPHTHALAN FOR THE TREATMENT OF ORAL MUCOSAL DISEASES Ana Andabak Rogulj, Ivan Alajbeg, Emir Dzanic, Department of Oral Medicine, School of Dental Medicine, University of Zagreb, Croatia Objectives: Nonaromatic naphthalan (NAVS) is a purified natural oil derivative, abundant in steranes (geogenic steroids). The purpose of this study is to evaluate the effectiveness of NAVS in the treatment of oral mucosal diseases including oral lichen planus (OLP), recurrent aphthous ulcerations (RAU), and cicatricial pemphigoid (CP). Methods: We applied NAVS oil in adhesive paste in patients with clinically and histologically proven OLP, in patients with RAU (double-blind and randomized; topical betamethasone in adhesive paste used as control), and in 1 participant with CP (open label), 3 times daily during 4 weeks. The severity of the OLP lesions was objectively scored. The number and diameter of RAU lesions were also assessed on days 3 and 5. The intensity of pain and discomfort was determined using a visual analog scale (VAS) and the Oral Health Impact Profile 14 (OHIP-14) before and after therapy. Statistical analysis was performed by use of the Wilcoxon test for paired samples to evaluate the effect of treatment in each group. Treatment effect between the groups was performed by Mann-Whitney test; values of P < .05 were considered significant. Results: The results of this study showed that NAVS has successfully reduced the clinical signs and symptoms of OLP; has reduced the number, diameter, and symptoms in patients with RAU statistically comparable with corticosteroids. NAVS has reduced clinical signs in 1 CP patient.
OOOO May 2014 Conclusions: These results indicate the good performance of NAVS as a potential alternative to corticosteroids in the treatment of oral mucosal diseases.
OI0364 EFFECTIVENESS OF BEXIDENT POST IN THE TREATMENT OF RECURRENT APHTHOUS STOMATITIS Enric de Clemente Rodríguez de Rivera, E. Rodríguez de Rivera Campillo, E. Jané Salas, R. Albuquerque, José López López, Department of Oral Medicine, University of Barcelona, Spain Objectives: Recurrent aphthous stomatitis (RAS) is the most common inflammatory ulcerative condition of the oral mucosa. It is characterized by multiple recurrent small, round ulcers with circumscribed margins, erythematous halos, and yellow or gray floors typically presenting first in childhood or adolescence. To date, the treatment remains empirical and nonspecific. The main goals of therapy are to minimize pain and functional disabilities as well as to decrease inflammatory reactions and frequency of recurrences. The aim of this study is to evaluate the effectiveness of Bexident Post in the control of the symptoms of RAS. The gel is composed of chlorhexidine digluconate (0.2%), chitosan (0.5%), dexpantenol (5%), allantoin (0.15%), and sodium saccharin (0.01%). Methods: A total of 25 patients with RAS were included. The product was applied 3 times per day. The patient could not eat, drink, or rinse during the first 15 minutes. A control was done on days 2 and 10. Results: Bexident Post was applied during an average of 5.08 days. Pain improved by 7.2 points (out of 10) 2 days after. In 10 days, the improvement was 9.4 points. An improvement of 7.2 points (2 days after the application) and 8.6 points (10 days after) was seen in the speaking difficulties. Eating limitations improved by 8.2 points 48 hours after and by 9 points after the first 10 days. The average product applicability was 8.44. The mean satisfaction rate was 8.56. Conclusions: The effectiveness of the product in the treatment of the symptoms of RAS has been demonstrated. There are no complications. Given the positive results obtained and its easy application, we highlight the importance of considering it as a handy treatment.
OI0410 ACCURACY OF LUGOL IODINE IN DETECTION OF ORAL CANCER Imad Elimairi, O. Abdoun, A. Sami, Department of Oral and Maxillofacial Surgery, Pathology and Oral Medicine, Ribat University and Nile College, Khartoum, Sudan Objectives: Using Lugol iodine shows great benefit in demarcating the exact extent of dysplastic mucosal changes. Iodine binds to the intracellular glycogen of epithelium, giving the normal mucosa a brown-black color while areas of dysplasia remain unstained. The purpose of this study is to detect the accuracy of Lugol iodine in determining the safe surgical margin in oral cancer and dysplasia. Methods: Patients attending the oral and maxillofacial surgery departments in Khartoum Teaching Dental Hospital (KTDH) and Ribat Hospital in Khartoum state complaining from oral suspicious lesions provisionally diagnosed as oral squamous cell carcinoma or dysplasia based on clinical examination were included. Lugol iodine solution was applied to the affected oral mucosa using cotton buds. Any color changes were recorded within 2 minutes of application using a digital camera. The
OI0268 NONAROMATIC NAPHTHALAN FOR THE TREATMENT OF ORAL MUCOSAL DISEASES Ana Andabak Rogulj, Ivan Alajbeg, Emir Dzanic, Department of Oral Medicine, School of Dental Medicine, University of Zagreb, Croatia Objectives: Nonaromatic naphthalan (NAVS) is a purified natural oil derivative, abundant in steranes (geogenic steroids). The purpose of this study is to evaluate the effectiveness of NAVS in the treatment of oral mucosal diseases including oral lichen planus (OLP), recurrent aphthous ulcerations (RAU), and cicatricial pemphigoid (CP). Methods: We applied NAVS oil in adhesive paste in patients with clinically and histologically proven OLP, in patients with RAU (double-blind and randomized; topical betamethasone in adhesive paste used as control), and in 1 participant with CP (open label), 3 times daily during 4 weeks. The severity of the OLP lesions was objectively scored. The number and diameter of RAU lesions were also assessed on days 3 and 5. The intensity of pain and discomfort was determined using a visual analog scale (VAS) and the Oral Health Impact Profile 14 (OHIP-14) before and after therapy. Statistical analysis was performed by use of the Wilcoxon test for paired samples to evaluate the effect of treatment in each group. Treatment effect between the groups was performed by Mann-Whitney test; values of P < .05 were considered significant. Results: The results of this study showed that NAVS has successfully reduced the clinical signs and symptoms of OLP; has reduced the number, diameter, and symptoms in patients with RAU statistically comparable with corticosteroids. NAVS has reduced clinical signs in 1 CP patient.
OOOO May 2014 Conclusions: These results indicate the good performance of NAVS as a potential alternative to corticosteroids in the treatment of oral mucosal diseases.
OI0364 EFFECTIVENESS OF BEXIDENT POST IN THE TREATMENT OF RECURRENT APHTHOUS STOMATITIS Enric de Clemente Rodríguez de Rivera, E. Rodríguez de Rivera Campillo, E. Jané Salas, R. Albuquerque, José López López, Department of Oral Medicine, University of Barcelona, Spain Objectives: Recurrent aphthous stomatitis (RAS) is the most common inflammatory ulcerative condition of the oral mucosa. It is characterized by multiple recurrent small, round ulcers with circumscribed margins, erythematous halos, and yellow or gray floors typically presenting first in childhood or adolescence. To date, the treatment remains empirical and nonspecific. The main goals of therapy are to minimize pain and functional disabilities as well as to decrease inflammatory reactions and frequency of recurrences. The aim of this study is to evaluate the effectiveness of Bexident Post in the control of the symptoms of RAS. The gel is composed of chlorhexidine digluconate (0.2%), chitosan (0.5%), dexpantenol (5%), allantoin (0.15%), and sodium saccharin (0.01%). Methods: A total of 25 patients with RAS were included. The product was applied 3 times per day. The patient could not eat, drink, or rinse during the first 15 minutes. A control was done on days 2 and 10. Results: Bexident Post was applied during an average of 5.08 days. Pain improved by 7.2 points (out of 10) 2 days after. In 10 days, the improvement was 9.4 points. An improvement of 7.2 points (2 days after the application) and 8.6 points (10 days after) was seen in the speaking difficulties. Eating limitations improved by 8.2 points 48 hours after and by 9 points after the first 10 days. The average product applicability was 8.44. The mean satisfaction rate was 8.56. Conclusions: The effectiveness of the product in the treatment of the symptoms of RAS has been demonstrated. There are no complications. Given the positive results obtained and its easy application, we highlight the importance of considering it as a handy treatment.
OI0410 ACCURACY OF LUGOL IODINE IN DETECTION OF ORAL CANCER Imad Elimairi, O. Abdoun, A. Sami, Department of Oral and Maxillofacial Surgery, Pathology and Oral Medicine, Ribat University and Nile College, Khartoum, Sudan Objectives: Using Lugol iodine shows great benefit in demarcating the exact extent of dysplastic mucosal changes. Iodine binds to the intracellular glycogen of epithelium, giving the normal mucosa a brown-black color while areas of dysplasia remain unstained. The purpose of this study is to detect the accuracy of Lugol iodine in determining the safe surgical margin in oral cancer and dysplasia. Methods: Patients attending the oral and maxillofacial surgery departments in Khartoum Teaching Dental Hospital (KTDH) and Ribat Hospital in Khartoum state complaining from oral suspicious lesions provisionally diagnosed as oral squamous cell carcinoma or dysplasia based on clinical examination were included. Lugol iodine solution was applied to the affected oral mucosa using cotton buds. Any color changes were recorded within 2 minutes of application using a digital camera. The